THIRD ROCK VENTURES LP 4
Accession 0000899243-18-020534
Filed
Jul 23, 8:00 PM ET
Accepted
Jul 24, 7:19 PM ET
Size
27.1 KB
Accession
0000899243-18-020534
Insider Transaction Report
- Conversion
Series E Preferred Stock
2018-07-23−2,285,640→ 0 total→ Common Stock (266,934 underlying) - Conversion
Series E-1 Preferred Stock
2018-07-23−3,107,930→ 0 total→ Common Stock (282,308 underlying) - Conversion
Common Stock
2018-07-23+2,705,334→ 2,716,384 total - Conversion
Series A Preferred Stock
2018-07-23−11,000,000→ 0 total→ Common Stock (999,180 underlying) - Conversion
Series B Preferred Stock
2018-07-23−10,650,000→ 0 total→ Common Stock (967,389 underlying) - Purchase
Common Stock
2018-07-23$15.00/sh+266,667$4,000,005→ 2,983,051 total - Conversion
Series D Preferred Stock
2018-07-23−1,086,411→ 0 total→ Common Stock (98,683 underlying) - Conversion
Series F Preferred Stock
2018-07-23−1,000,000→ 0 total→ Common Stock (90,840 underlying)
- Purchase
Common Stock
2018-07-23$15.00/sh+266,667$4,000,005→ 2,983,051 total - Conversion
Series D Preferred Stock
2018-07-23−1,086,411→ 0 total→ Common Stock (98,683 underlying) - Conversion
Common Stock
2018-07-23+2,705,334→ 2,716,384 total - Conversion
Series B Preferred Stock
2018-07-23−10,650,000→ 0 total→ Common Stock (967,389 underlying) - Conversion
Series E Preferred Stock
2018-07-23−2,285,640→ 0 total→ Common Stock (266,934 underlying) - Conversion
Series E-1 Preferred Stock
2018-07-23−3,107,930→ 0 total→ Common Stock (282,308 underlying) - Conversion
Series A Preferred Stock
2018-07-23−11,000,000→ 0 total→ Common Stock (999,180 underlying) - Conversion
Series F Preferred Stock
2018-07-23−1,000,000→ 0 total→ Common Stock (90,840 underlying)
- Purchase
Common Stock
2018-07-23$15.00/sh+266,667$4,000,005→ 2,983,051 total - Conversion
Common Stock
2018-07-23+2,705,334→ 2,716,384 total - Conversion
Series E Preferred Stock
2018-07-23−2,285,640→ 0 total→ Common Stock (266,934 underlying) - Conversion
Series F Preferred Stock
2018-07-23−1,000,000→ 0 total→ Common Stock (90,840 underlying) - Conversion
Series B Preferred Stock
2018-07-23−10,650,000→ 0 total→ Common Stock (967,389 underlying) - Conversion
Series A Preferred Stock
2018-07-23−11,000,000→ 0 total→ Common Stock (999,180 underlying) - Conversion
Series D Preferred Stock
2018-07-23−1,086,411→ 0 total→ Common Stock (98,683 underlying) - Conversion
Series E-1 Preferred Stock
2018-07-23−3,107,930→ 0 total→ Common Stock (282,308 underlying)
- Conversion
Series E-1 Preferred Stock
2018-07-23−3,107,930→ 0 total→ Common Stock (282,308 underlying) - Conversion
Common Stock
2018-07-23+2,705,334→ 2,716,384 total - Conversion
Series A Preferred Stock
2018-07-23−11,000,000→ 0 total→ Common Stock (999,180 underlying) - Conversion
Series D Preferred Stock
2018-07-23−1,086,411→ 0 total→ Common Stock (98,683 underlying) - Conversion
Series E Preferred Stock
2018-07-23−2,285,640→ 0 total→ Common Stock (266,934 underlying) - Conversion
Series F Preferred Stock
2018-07-23−1,000,000→ 0 total→ Common Stock (90,840 underlying) - Purchase
Common Stock
2018-07-23$15.00/sh+266,667$4,000,005→ 2,983,051 total - Conversion
Series B Preferred Stock
2018-07-23−10,650,000→ 0 total→ Common Stock (967,389 underlying)
- Conversion
Series B Preferred Stock
2018-07-23−10,650,000→ 0 total→ Common Stock (967,389 underlying) - Conversion
Series D Preferred Stock
2018-07-23−1,086,411→ 0 total→ Common Stock (98,683 underlying) - Purchase
Common Stock
2018-07-23$15.00/sh+266,667$4,000,005→ 2,983,051 total - Conversion
Series F Preferred Stock
2018-07-23−1,000,000→ 0 total→ Common Stock (90,840 underlying) - Conversion
Common Stock
2018-07-23+2,705,334→ 2,716,384 total - Conversion
Series A Preferred Stock
2018-07-23−11,000,000→ 0 total→ Common Stock (999,180 underlying) - Conversion
Series E Preferred Stock
2018-07-23−2,285,640→ 0 total→ Common Stock (266,934 underlying) - Conversion
Series E-1 Preferred Stock
2018-07-23−3,107,930→ 0 total→ Common Stock (282,308 underlying)
Footnotes (2)
- [F1]On July 23, 2018, the Series A, Series B, Series D, Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B, Series C, Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.
- [F2]These securities are directly held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares
Documents
Issuer
CONSTELLATION PHARMACEUTICALS INC
CIK 0001434418
Related Parties
1- filerCIK 0001408591
Filing Metadata
- Form type
- 4
- Filed
- Jul 23, 8:00 PM ET
- Accepted
- Jul 24, 7:19 PM ET
- Size
- 27.1 KB